View Older Stories View More Recent Stories

May 3, 2023 04:01PM Personalis Reports First Quarter 2023 Financial Results
May 2, 2023 08:03AM Personalis, (PSNL) ABRCC and Criterium Announce Prospective Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer
May 2, 2023 08:00AM Personalis, ABRCC, and Criterium Announce Major Prospective Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer
Apr 19, 2023 04:01PM Personalis to Announce First Quarter 2023 Financial Results
Apr 5, 2023 04:01PM Personalis to Participate at the 22nd Annual Needham Virtual Healthcare Conference
Apr 5, 2023 08:45AM Personalis Joins Top UK Cancer Research Organizations to Evaluate Earlier Cancer Recurrence Detection Through Groundbreaking Study
Mar 22, 2023 08:55AM Personalis Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2023
Mar 7, 2023 08:56AM Personalis (PSNL) will continue its collaboration with AstraZeneca to explore ultra-sensitive molecular residual disease measurement
Mar 7, 2023 08:55AM Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay
Mar 2, 2023 04:06PM Personalis, Inc. (PSNL) Appoints Christopher Hall as CEO
Mar 2, 2023 04:05PM Personalis Appoints Christopher Hall as Chief Executive Officer
Feb 23, 2023 04:01PM Personalis Reports Fourth Quarter and Full Year 2022 Financial Results
Feb 9, 2023 04:01PM Personalis to Announce Fourth Quarter and Full Year 2022 Financial Results
Feb 6, 2023 04:01PM Personalis to Participate at Upcoming Investor Conferences
Feb 3, 2023 08:46AM Personalis (PSNL), Moderna (MRNA) Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
Feb 3, 2023 08:45AM Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
Jan 4, 2023 04:05PM Personalis, Inc. (PSNL) Prelim. Q4 Revenue Tops Consensus
Jan 4, 2023 04:01PM Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue
Dec 16, 2022 04:05PM Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 14, 2022 04:02PM Personalis Announces CEO Retirement and Transition
Nov 30, 2022 08:55AM Personalis, Inc. (PSNL) and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer
Nov 30, 2022 08:55AM Personalis and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer
Nov 21, 2022 04:01PM Personalis to Present at the 34th Annual Piper Sandler Healthcare Conference
Nov 7, 2022 04:05PM Personalis Presents Data from New Platform Features at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Nov 2, 2022 04:01PM Personalis Reports Third Quarter 2022 Financial Results
Oct 31, 2022 04:16PM Personalis Grows Leadership Team with Appointment of Christopher Hall as Senior Vice President and Head, Diagnostics Business
Oct 19, 2022 04:01PM Personalis to Announce Third Quarter 2022 Financial Results
Oct 4, 2022 09:00AM Personalis Forms Research Collaboration to Better Predict Immunotherapy Response for Gastroesophageal Cancer
Aug 30, 2022 04:01PM Personalis to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
Aug 17, 2022 04:15PM Personalis Adds New MRD Patent Covering the Combination of Tumor-Informed and Database-Derived Content to Patent Infringement Complaint Against Foresight Diagnostics
Aug 16, 2022 04:05PM Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 15, 2022 08:55AM Personalis in Partnership with BC Cancer to Assess Clinical and Economic Benefits of ctDNA for Colorectal and Pancreatic Cancers
Aug 4, 2022 04:01PM Personalis to Participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference
Aug 3, 2022 04:01PM Personalis Reports Second Quarter 2022 Financial Results
Aug 2, 2022 04:11PM Personalis (PSNL) Files Patent Infringement Lawsuit Against Foresight Diagnostics
Aug 2, 2022 04:10PM Personalis Files Patent Infringement Lawsuit Against Foresight Diagnostics
Jul 20, 2022 04:01PM Personalis to Announce Second Quarter 2022 Financial Results
Jul 12, 2022 04:06PM Personalis (PSNL) Granted New Patent Related to Tumor-Informed Detection of Molecular Residual Disease
Jul 12, 2022 04:05PM Personalis Announces Expansion of Its Patent Portfolio Related to Tumor-Informed Detection of Molecular Residual Disease
May 4, 2022 04:01PM Personalis Reports First Quarter 2022 Financial Results
Apr 28, 2022 04:01PM Personalis to Present at Upcoming Investor Conferences
Apr 26, 2022 08:45AM Evaxion to Utilize Personalis’ ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma
Apr 21, 2022 09:00AM Personalis Expands Diagnostic Leadership Team With Appointment of James Azzaro, Vice President of Diagnostic Sales
Apr 20, 2022 04:01PM Personalis to Announce First Quarter 2022 Financial Results
Apr 12, 2022 08:56AM Personalis (PSNL) Reports Publication of New Data Demonstrating Highly Sensitive Algorithm for Detecting Loss of Heterozygosity in HLA Gene
Apr 12, 2022 08:55AM Personalis Publishes New Data Demonstrating Highly Sensitive Algorithm for Detecting Loss of Heterozygosity in HLA Gene
Apr 12, 2022 08:30AM Personalis Announces Issuance of Additional US Patent Related to the NeXT Personal™ Platform
Apr 11, 2022 09:00AM Personalis and Merck KGaA, Darmstadt, Germany to Present Comprehensive Tumor Subtyping Collaboration Data at AACR Annual Meeting 2022
Mar 31, 2022 04:01PM Personalis to Present at the 21st Annual Needham Virtual Healthcare Conference
Mar 24, 2022 06:25PM Diagnostic Industry Veteran Karin Eastham to Chair Personalis Board of Directors
View More Recent Stories View Older Stories